Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDRX NASDAQ:ENTO NASDAQ:SCNI NASDAQ:XBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$3.28$3.58$2.86▼$66.50$6.55M1.15980,105 shs19,931 shsENTOEntero Therapeutics$4.84+5.0%$2.63$0.32▼$5.84$7.69M1.192.80 million shs182,784 shsSCNIScinai Immunotherapeutics$0.46$0.59$0.44▼$6.18$1.63M2.1910.40 million shs148,697 shsXBIOXenetic Biosciences$3.03$3.07$1.90▼$13.93$6.94M2.210,898 shs19,695 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals0.00%+4.13%-0.61%-41.43%-94.30%ENTOEntero Therapeutics0.00%+25.06%+113.22%+87.60%+324.67%SCNIScinai Immunotherapeutics0.00%-17.64%-37.42%-46.31%-83.23%XBIOXenetic Biosciences0.00%+3.41%-0.66%+28.39%-1.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$3.28$3.58$2.86▼$66.50$6.55M1.15980,105 shs19,931 shsENTOEntero Therapeutics$4.84+5.0%$2.63$0.32▼$5.84$7.69M1.192.80 million shs182,784 shsSCNIScinai Immunotherapeutics$0.46$0.59$0.44▼$6.18$1.63M2.1910.40 million shs148,697 shsXBIOXenetic Biosciences$3.03$3.07$1.90▼$13.93$6.94M2.210,898 shs19,695 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals0.00%+4.13%-0.61%-41.43%-94.30%ENTOEntero Therapeutics0.00%+25.06%+113.22%+87.60%+324.67%SCNIScinai Immunotherapeutics0.00%-17.64%-37.42%-46.31%-83.23%XBIOXenetic Biosciences0.00%+3.41%-0.66%+28.39%-1.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals 1.00SellN/AN/AENTOEntero Therapeutics 1.00SellN/AN/ASCNIScinai Immunotherapeutics 1.00SellN/AN/AXBIOXenetic Biosciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SCNI, XBIO, BDRX, and ENTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/29/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026SCNIScinai Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026XBIOXenetic Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$470K13.96N/AN/A$110.30 per share0.03ENTOEntero TherapeuticsN/AN/AN/AN/A($2.45) per shareN/ASCNIScinai Immunotherapeutics$1.31M1.25N/AN/A$0.78 per share0.59XBIOXenetic Biosciences$2.98M2.33N/AN/A$3.03 per share1.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$8.42MN/AN/AN/AN/AN/AN/AN/AN/AENTOEntero Therapeutics-$18.06M-$1.69N/AN/AN/AN/A-461.02%-14.72%N/ASCNIScinai Immunotherapeutics-$8.31M-$9.57N/AN/AN/AN/AN/AN/A7/7/2026 (Estimated)XBIOXenetic Biosciences-$2.68M-$1.20N/AN/AN/A-70.03%-39.28%-33.47%8/7/2026 (Estimated)Latest SCNI, XBIO, BDRX, and ENTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026XBIOXenetic BiosciencesN/A-$0.20N/A-$0.20N/A$0.81 million4/1/2026Q4 2025SCNIScinai ImmunotherapeuticsN/A$3.80N/A$3.80N/A$0.27 million3/27/2026Q4 2025BDRXBiodexa Pharmaceuticals-$0.0066$3.5250+$3.5316-$5.35N/AN/A3/12/2026Q4 2025XBIOXenetic Biosciences-$0.52-$0.22+$0.30-$0.22$0.69 million$0.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AENTOEntero TherapeuticsN/AN/AN/AN/AN/ASCNIScinai ImmunotherapeuticsN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa PharmaceuticalsN/A2.032.03ENTOEntero TherapeuticsN/A2.622.62SCNIScinai Immunotherapeutics0.121.301.30XBIOXenetic BiosciencesN/A7.937.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%ENTOEntero Therapeutics12.30%SCNIScinai Immunotherapeutics58.41%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%ENTOEntero Therapeutics0.75%SCNIScinai Immunotherapeutics60.90%XBIOXenetic Biosciences7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals202.00 million1.99 millionNot OptionableENTOEntero Therapeutics91.59 million3.34 millionN/ASCNIScinai Immunotherapeutics203.54 million1.38 millionNot OptionableXBIOXenetic Biosciences42.29 million2.12 millionNot OptionableSCNI, XBIO, BDRX, and ENTO HeadlinesRecent News About These CompaniesCritical Survey: Nature's Sunshine Products (NASDAQ:NATR) and Xenetic Biosciences (NASDAQ:XBIO)May 19, 2026 | americanbankingnews.comXenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology PlatformMay 13, 2026 | accessnewswire.comAXenetic Biosciences: Q1 Earnings SnapshotMay 12, 2026 | wtop.comWXenetic Biosciences Grants Equity Award to Interim CEOApril 27, 2026 | theglobeandmail.comXenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual MeetingApril 22, 2026 | accessnewswire.comAXenetic Biosciences, Inc. Reports Full Year 2025 Financial ResultsMarch 13, 2026 | accessnewswire.comAXenetic Biosciences, Inc. Announces Adjournment of 2025 Annual MeetingDecember 11, 2025 | accessnewswire.comAXenetic extends R&D collaboration with The Scripps Research InstituteNovember 19, 2025 | msn.comXenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase PlatformNovember 19, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports Third Quarter 2025 Financial ResultsNovember 13, 2025 | accessnewswire.comAXenetic Biosciences Announces Public Offering PricingOctober 14, 2025 | msn.comXenetic 735,000 share Spot Secondary priced at $6.12October 10, 2025 | msn.comMicron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking SurgesOctober 10, 2025 | benzinga.comXenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common StockOctober 10, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | accessnewswire.comAXenetic Biosciences Reports Improved Financial PerformanceAugust 13, 2025 | msn.comXenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue EstimatesAugust 12, 2025 | zacks.comXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell LymphomaJuly 30, 2025 | accessnewswire.comAXenetic Biosciences expands R&D collaboration with The Scripps Research Institute to advance DNase platformJuly 26, 2025 | pharmabiz.comPXenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformJuly 23, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCNI, XBIO, BDRX, and ENTO Company DescriptionsBiodexa Pharmaceuticals NASDAQ:BDRX$3.28 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.72 +0.44 (+13.54%) As of 05/22/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Entero Therapeutics NASDAQ:ENTO$4.84 +0.23 (+4.99%) As of 05/22/2026Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Scinai Immunotherapeutics NASDAQ:SCNI$0.46 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.47 +0.01 (+2.12%) As of 05/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.Xenetic Biosciences NASDAQ:XBIO$3.03 0.00 (0.00%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$2.88 -0.15 (-4.79%) As of 05/22/2026 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
